Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Not yet recruiting × tucatinib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1 1

Status

Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cisplatin 9 Carboplatin 7 Capecitabine 6 Oxaliplatin 5 Fluorouracil 5 Gemcitabine 4 Drug Therapy 4 130-nm albumin-bound paclitaxel 4 venetoclax 3 sintilimab 3 pembrolizumab 3 Trastuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Cyclophosphamide 3 trametinib 2 pertuzumab 2 fludarabine 2 dabrafenib 2 camrelizumab 2 blinatumomab 2 apatinib 2 Surgical Procedures, Operative 2 Radiosurgery 2 Pemetrexed 2 Leucovorin 2 Docetaxel 2 Androgen Antagonists 2 vedolizumab 1 tucatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡